2024.Jun.07
Corporate
OBI Pharma at BIO USA 2024
OBI showcased its proprietary ADC platform GlycOBI™ and attracted significant interest from the audience significant interest from the audience On June 4th, OBI Pharma from Taiwan made a notable appearance at BIO USA 2024. The company introduced its proprietary ADC (Antibody-Drug Conjugate) technology platform, GlycOBI™, which quickly garnered significant interest. This platform enables site-specific conjugation […]
This article is password protected.
To view the content, please enter your password in the field below